Why is DocGo stock sliding today?

DocGo shares are down nearly 12.7% pre-open after Q2 2026 results missed on both lines, with adjusted EPS of -$0.16 vs -$0.10 consensus and revenue of $73.4M vs $75.4M. The stock took a bigger hit from guidance as DocGo widened its full-year 2026 adjusted EBITDA loss to -$17M to -$22M (from a prior -$5M to -$10M). The negative read-through is compounded by its planned acquisition of Hicuity Health (~$65M trailing revenue) structured with about $52M of assumed debt and up to $50M in new financing commitments. With U.S. index futures pressured on renewed U.S.-Iran ceasefire concerns, the risk-off tape is intensifying downside for small-cap, high-beta names like DocGo.

Analysis

The stock is behaving like a financing event, not an earnings event: once a sub-$1 equity starts missing guidance while adding debt-funded acquisitions, the market tends to price the common as residual value with high dilution risk. The key second-order effect is that the Hicuity deal likely increases the cost of capital for any future growth initiative, because lenders and equity backers will now underwrite to a weaker EBITDA bridge and a more fragile transition away from the legacy revenue base.

The immediate losers are DocGo shareholders and, more broadly, any small-cap healthcare services name trying to pivot via M&A while still burning cash. In contrast, better-capitalized telehealth assets like TDOC/AMWL should not be judged on the same rubric; if anything, this situation reinforces a quality premium for companies that can fund growth without leaning on debt assumptions. On the operating side, management’s core business may still be improving, but the market will discount that until it sees 2-3 consecutive quarters of sequential EBITDA improvement and no incremental capital raise.

The contrarian view is that the downside may become less linear if the financing closes cleanly and the company proves the medical transportation base is stabilizing. But the burden of proof is high: the equity needs evidence that cash burn is falling faster than the integration drag from Hicuity. If a follow-on equity raise, covenant reset, or weaker-than-expected Q3 appears, this likely becomes a restructure/zero-to-little-value narrative over the next 1-3 months rather than a simple sentiment washout.

Key Decisions for Investors

• Short DCGO only on any relief rally into the $0.75-$0.85 area over the next 2-4 weeks; target a retest of sub-$0.50 if financing terms remain debt-heavy. Risk: a cleaner-than-feared close on Hicuity financing or an unexpected strategic bid could trigger a squeeze in a name this small.
• If borrow is tight, use a small, defined-risk put spread on DCGO into the next earnings/financing update window; this is a catalyst trade, not a core short. Falsify the thesis if management shows sequential EBITDA improvement and no need for incremental capital.
• Pair trade: long TDOC / short DCGO for 1-3 months as a quality-vs-distress expression in telehealth. The spread should work if investors continue to reward scale, liquidity, and clean balance sheets while punishing microcap turnaround stories.
• Avoid bottom-fishing DCGO until after the next disclosure of cash balance, covenant headroom, and pro forma leverage. If those metrics do not stabilize, the equity remains a call option on execution with poor odds.